Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Opus Genetics, Inc.NASDAQ: IRD
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 67.6% from a year ago
Other current liabilities stood at $4.12M at the end of Q1 FY2026, down 67.6% from a year earlier and down 8.1% from the prior quarter.
Context
- Other current liabilities amounted to 6.2% of total assets at the end of Q1 FY2026, down 20.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -67.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.49M USD
- Year-over-year change
- +224300.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.49M | +224300.0% |
| FY2024 | 2024-12-31 | 2K | -97.3% |
| FY2023 | 2023-12-31 | 74K | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 other current liabilities of $4.12M is the 4th highest of the 10 companies compared; the peer median is $2.25M.
- Its year-over-year change of -67.6% is the 7th highest of 10, against a peer median of +24.3%.
- Other current liabilities amounts to 6.2% of total assets for IRD, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.15M | -74.2% | -6.4% | 15.1% | |
| Mar 2026 | $27.02M | +70.3% | +34.0% | 54.3% | |
| Mar 2026 | $4.3M | +63.4% | -49.2% | 3.7% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.12M | -67.6% | — | 6.2% |
| Mar 2026 | $3M | +101.8% | -3.9% | 1.1% | |
| Mar 2026 | $2.25M | +150.8% | -15.9% | 1.1% | |
| Mar 2026 | $1.61M | +24.3% | +218.8% | 1.2% | |
| Mar 2026 | $498K | -17.0% | +21.7% | 1.4% | |
| Mar 2026 | $197.59K | -86.4% | +31.2% | 0.7% | |
| Mar 2026 | $0 | -100.0% | +24.1% | 0.0% | |
| Peer median (excluding IRD) | $2.25M | +24.3% | +21.7% | 1.2% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.